Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

mAbs

Showing results (381-390 of 1,833) with videos related to

Pageof 184
Sort By:
Mabs|January 17, 2025
With great power, comes great responsibility: the importance of broadly measuring Fc-mediated effector function early in the antibody development processSilvia Crescioli, Shashi Jatiani, Lenny Moise
Mabs|December 9, 2024
A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancerPeter Jung, Stefan P Glaser, Jing Han, et al.
Mabs|December 5, 2023
Breaking barriers in antibody discovery: harnessing divergent species for accessing difficult and conserved drug targetsSoma S R Banik, Natasha Kushnir, Benjamin J Doranz, et al.
Mabs|March 27, 2024
In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodiesAimee E Mattei, Andres H Gutierrez, Soorya Seshadri, et al.
Mabs|March 26, 2024
RUBY® - a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability propertiesBarnabas Nyesiga, Mattias Levin, Anna Säll, et al.
Mabs|September 17, 2024
Sequence-based engineering of pH-sensitive antibodies for tumor targeting or endosomal recycling applicationsWanlei Wei, Traian Sulea
Mabs|September 21, 2024
Discovery of potent allosteric antibodies inhibiting EGFRLéxane Fournier, Lukas Pekar, Birgitta Leuthner, et al.
Mabs|September 22, 2024
Systematic analysis of Fc mutations designed to enhance binding to Fc-gamma receptorsGeoff Hale, Alastair Douglas Davy, Ian Wilkinson
Mabs|March 6, 2024
Exploring molecular determinants and pharmacokinetic properties of IgG1-scFv bispecific antibodiesKristina M J Aertker, Minu Ravindra Pilvankar, Tobias M Prass, et al.
Mabs|March 6, 2024
A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapyGerhard Frey, Ana Paula G Cugnetti, Haizhen Liu, et al.
Pageof 184

Showing results (381-390 of 1,833) with videos related to

Sort By:
Pageof 184
Mabs|January 17, 2025
With great power, comes great responsibility: the importance of broadly measuring Fc-mediated effector function early in the antibody development processSilvia Crescioli, Shashi Jatiani, Lenny Moise
Mabs|December 9, 2024
A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancerPeter Jung, Stefan P Glaser, Jing Han, et al.
Mabs|December 5, 2023
Breaking barriers in antibody discovery: harnessing divergent species for accessing difficult and conserved drug targetsSoma S R Banik, Natasha Kushnir, Benjamin J Doranz, et al.
Mabs|March 27, 2024
In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodiesAimee E Mattei, Andres H Gutierrez, Soorya Seshadri, et al.
Mabs|March 26, 2024
RUBY® - a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability propertiesBarnabas Nyesiga, Mattias Levin, Anna Säll, et al.
Mabs|September 17, 2024
Sequence-based engineering of pH-sensitive antibodies for tumor targeting or endosomal recycling applicationsWanlei Wei, Traian Sulea
Mabs|September 21, 2024
Discovery of potent allosteric antibodies inhibiting EGFRLéxane Fournier, Lukas Pekar, Birgitta Leuthner, et al.
Mabs|September 22, 2024
Systematic analysis of Fc mutations designed to enhance binding to Fc-gamma receptorsGeoff Hale, Alastair Douglas Davy, Ian Wilkinson
Mabs|March 6, 2024
Exploring molecular determinants and pharmacokinetic properties of IgG1-scFv bispecific antibodiesKristina M J Aertker, Minu Ravindra Pilvankar, Tobias M Prass, et al.
Mabs|March 6, 2024
A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapyGerhard Frey, Ana Paula G Cugnetti, Haizhen Liu, et al.
Pageof 184